PROGSK plc
stock1,771.00p
+21.00 (+1.20%)
Price as of 13 Oct, 15:41 · Rate limit reached. Please try again in a minute.
Good Money Guide Pro Score
Neutral
Mixed investment profile
Technical Analysis
Short-Term Outlook
Bearish
1 bull · 2 bear · 2 neutral
Medium-Term Outlook
Bearish
0 bull · 4 bear · 0 neutral
Price below 50-day MA
Price below 200-day MA
Price below 12-day EMA
Price below 26-day EMA
Neutral momentum zone
MACD below signal line
Oversold — potential reversal up
Price near middle band
Volatility measure — informational only
Market Statistics
Day Change
+21.00p
Exchange
LSE
Sector
Pharmaceuticals & biotechnology
FCA Net Short Position
Position date: 09 Oct 2026
The aggregated net short position reported to the FCA by all position holders with positions ≥ 0.2%.
Fundamentals
Rate limit reached. Please try again in a minute.
Analyst Forecast
Rate limit reached. Please try again in a minute.
Learn about GSK plc
What is GSK plc?
GSK plc is a global biopharma company focused on uniting science, technology, and talent to get ahead of disease together. The company researches, develops, and manufactures a wide range of vaccines and specialty medicines to treat conditions like infectious diseases, HIV, oncology, and respiratory illnesses.
Is GSK plc a good investment?
GSK offers potential appeal through its strong portfolio of vaccines and stable dividend payments, but it faces risks such as patent cliffs and high costs associated with drug development and legal challenges. Deciding whether it fits your portfolio depends on your risk tolerance and investment goals, and please note that this information is for educational purposes and not financial advice.
How do you invest in GSK plc?
You can gain exposure to GSK plc by purchasing shares directly through a regulated online stockbroker or investment platform that provides access to the London Stock Exchange or the New York Stock Exchange. Alternatively, you may gain indirect exposure by investing in healthcare-focused exchange-traded funds (ETFs) or mutual funds that hold the stock within their broader portfolios.
Educational content generated by AI — not financial advice.
Time & Sales
No trades yet.
News & Sentiment
Rate limit reached. Please try again in a minute.
Community Discussion
No posts yet for GSK — be the first to start the discussion.
Point & Figure Analysis
Famous Investors Holding GSK
Ray Dalio
504.2K sh · 0.1% of portfolio
$26.43M
NEW
Ken Griffin
387.7K sh · 0.0% of portfolio
$20.32M
NEW
Ken Griffin
331.6K sh · 0.0% of portfolio
$17.38M
NEW
Ken Griffin
151.6K sh · 0.0% of portfolio
$7.95M
NEW
Ken Griffin
1 sh · 0.0% of portfolio
$52
NEW
Source: SEC Form 13F, reporting period 30 Jun 2026. 45-day lag applies.